Cost-effectiveness of vaccination against meningococcal B among Dutch infants

References

• Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12:389 - 94; http://dx.doi.org/10.1097/00006454-199305000-00008; PMID: 8327300
   PubMed Web of Science ®Google Scholar
• Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:317 - 28; http://dx.doi.org/10.1016/S1473-3099(10)70048-7; PMID: 20417414
   PubMed Web of Science ®Google Scholar
• Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis 2011; 53:e117 - 24; http://dx.doi.org/10.1093/cid/cir500; PMID: 21946191
   PubMed Web of Science ®Google Scholar
• Healy CM, Butler KM, Smith EO, Hensey OP, Bate T, Moloney AC, et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 2002; 34:1323 - 30; http://dx.doi.org/10.1086/340050; PMID: 11981727
   PubMed Web of Science ®Google Scholar
• Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 1994; 112:115 - 24; http://dx.doi.org/10.1017/S0950268800057472; PMID: 8119350
   PubMed Web of Science ®Google Scholar
• Spanjaard L, Bol P, de Marie S, Zanen HC. Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull World Health Organ 1987; 65:861 - 8; PMID: 3124970
   PubMed Web of Science ®Google Scholar
• Netherlands Reference Laboratory for Bacterial Meningitis. Amsterdam: University of Amsterdam. Bacterial meningitis in the Netherlands: Annual reports 2006-2009.
   Google Scholar
• Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30:Suppl 2 B87 - 97; http://dx.doi.org/10.1016/j.vaccine.2012.01.033; PMID: 22607904
   PubMed Web of Science ®Google Scholar
• Novartis. Media release. Novartis receives positive CHMP opinion for Bexsero®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe. Available at: http://www.novartis.com/newsroom/media-releases/en/2012/1658747.shtml.
   Google Scholar
• Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 2001; 20:202 - 7; http://dx.doi.org/10.1016/S0264-410X(01)00254-7; PMID: 11567765
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Poolman JT, Lind I, Jónsdóttir K, Frøholm LO, Jones DM, Zanen HC. Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet 1986; 2:555 - 8; http://dx.doi.org/10.1016/S0140-6736(86)90123-6; PMID: 2875290
   PubMed Web of Science ®Google Scholar
• Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 2004; 23:470 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.06.019; PMID: 15530695
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011.
   Google Scholar
• Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007; 12:1409 - 21; http://dx.doi.org/10.1111/j.1365-3156.2007.01929.x; PMID: 17961128
   PubMed Web of Science ®Google Scholar
• Health Council. (GezondheidsRaad; GR). The future of the national immunization program: Towards a program for all ages. The Hague: GR, 2007. Available at: http://www.gezondheidsraad.nl/sites/default/files/200702E_0.pdf.
   Google Scholar
• Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, et al, 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597 - 607; http://dx.doi.org/10.1016/S1473-3099(12)70087-7; PMID: 22569484
   PubMed Web of Science ®Google Scholar
• McNicholas A, Galloway Y, Stehr-Green P, Reid S, Radke S, Sexton K, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin 2007; 3:196 - 204; http://dx.doi.org/10.4161/hv.3.5.4458; PMID: 17660718
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al, European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573 - 82; http://dx.doi.org/10.1001/jama.2012.85; PMID: 22318278
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737 - 43; http://dx.doi.org/10.1086/527401; PMID: 18271745
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851 - 61; http://dx.doi.org/10.1586/erv.09.48; PMID: 19538112
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23:76 - 82; http://dx.doi.org/10.1177/0272989X02239651; PMID: 12583457
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, García M, Mateo Sd. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 23:4097 - 100; http://dx.doi.org/10.1016/j.vaccine.2005.03.045; PMID: 15908059
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70251-6; PMID: 21075057
   PubMed Web of Science ®Google Scholar
• Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 2010; 28:449 - 61; http://dx.doi.org/10.2165/11535280-000000000-00000; PMID: 20465314
   PubMed Web of Science ®Google Scholar
• Christie D, Viner RM, Knox K, Coen PG, Wang H, El Bashir H, et al. Long-term outcomes of pneumococcal meningitis in childhood and adolescence. Eur J Pediatr 2011; 170:997 - 1006; http://dx.doi.org/10.1007/s00431-010-1390-5; PMID: 21246216
   PubMed Web of Science ®Google Scholar
• Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Pharmacoeconomics 2006; 24:141 - 53; http://dx.doi.org/10.2165/00019053-200624020-00004; PMID: 16460135
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Schouls LM, Spanjaard L, van Deuren M. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis 2008; 27:985 - 92; http://dx.doi.org/10.1007/s10096-008-0535-1; PMID: 18493804
   PubMed Web of Science ®Google Scholar
• Domínguez A, Cardeñosa N, Pañella H, Orcau A, Companys M, Alseda M, et al, Working Group on the Study of Meningococcal Disease in Catalonia, 1990-1997. The case-fatality rate of meningococcal disease in Catalonia, 1990-1997. Scand J Infect Dis 2004; 36:274 - 9; http://dx.doi.org/10.1080/00365540410020163; PMID: 15198184
   PubMed Web of Science ®Google Scholar
• Shigematsu M, Davison KL, Charlett A, Crowcroft NS. National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001. Epidemiol Infect 2002; 129:459 - 70; http://dx.doi.org/10.1017/S0950268802007549; PMID: 12558328
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Olcén P, Löfdahl M, Fredlund H, Mölling P. Characteristics of Neisseria meningitidis isolates causing fatal disease. Scand J Infect Dis 2008; 40:734 - 44; http://dx.doi.org/10.1080/00365540802029565; PMID: 19086340
   PubMed Web of Science ®Google Scholar
• Tsolia MN, Theodoridou M, Tzanakaki G, Vlachou V, Mostrou G, Stripeli F, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006; 25:449 - 56; http://dx.doi.org/10.1007/s10096-006-0155-6; PMID: 16773393
   PubMed Web of Science ®Google Scholar
• Biebl A, Hartmann G, Bernhard C, Bechter E, Luckner-Hornischer A, Frühwirth M, et al. Vaccine strategies of meningococcal disease: results of a 10-year population-based study. Eur J Pediatr 2005; 164:735 - 40; http://dx.doi.org/10.1007/s00431-005-1719-7; PMID: 16133244
   PubMed Web of Science ®Google Scholar
• Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27:4776 - 83; http://dx.doi.org/10.1016/j.vaccine.2009.05.085; PMID: 19539578
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, Edmunds WJ. Modelling the potential impact of MenB vaccines. Presented at: 8th Meningitis Research Foundation International Conference 2011, London, United Kingdom, 8-9 November 2011.
   Google Scholar
• Christensen H, Trotter CL, Hickman M, Edmunds WJ. Modelling the cost-effectiveness of new meningococcal vaccines in England. Presented at: 17th International Pathogenic Neisseria Conference, Banff, Alberta, Canada, 11-16 September 2010.
   Google Scholar
• Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Guidelines for costing research, methods and standarized prices for economic evaluations in health care. Dutch Health Care Insurance Board, 2010.
   Google Scholar
• de Greeff SC, Spanjaard L, Dankert J, Hoebe CJ, Nagelkerke N, de Melker HE. Underreporting of meningococcal disease incidence in the Netherlands: results from a capture-recapture analysis based on three registration sources with correction for false positive diagnoses. Eur J Epidemiol 2006; 21:315 - 21; http://dx.doi.org/10.1007/s10654-006-0020-z; PMID: 16685583
   PubMed Web of Science ®Google Scholar
• Kiwa Prismant. Independent nation-wide hospital registry [in Dutch]. Available at: http://cognosserver.prismant.nl/cognos7/cgi-bin/ppdscgi.cgi?DC=Q&E=/Prisma-Landelijke-LMR/Landelijke+LMR-informatie+-+Diagnosen
   Google Scholar
• Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 2009; 94:381 - 6; http://dx.doi.org/10.1136/adc.2007.131862; PMID: 19147623
   PubMed Web of Science ®Google Scholar
• Gruteke P, Postma MJ, Grosheide PM. Prevention of congenital syphilis: Economic evaluation using surveillance of the public-health laboratories [in Dutch]. Bilthoven, the Netherlands: National Institute of Public Health & the Environment (RIVM); 1995.
   Google Scholar
• Minne B, Webbink D, van der Wiel H. Special care for children with learning and/or behavioural difficulties. Netherlands Bureau for Economic Policy Analysis. The Hague, the Netherlands. 192, 2006.
   Google Scholar
• Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010; 340:c2509; http://dx.doi.org/10.1136/bmj.c2509; PMID: 20519267
   PubMed Web of Science ®Google Scholar
• Schippers EI. Available at: http://www.rijksoverheid.nl/bestanden/documenten-en-publicaties/kamerstukken/2011/04/21/antwoorden-kamervragen-niet-vergoeden-tweede-cochleaire-implantaat-bij-jonge-kinderen/antwoorden-kamervragen-niet-vergoeden-tweede-cochleaire-implantaat-bij-jonge-kinderen.pdf.
   Google Scholar
• Krabbe PF, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care 2000; 16:864 - 73; http://dx.doi.org/10.1017/S0266462300102132; PMID: 11028141
   PubMed Web of Science ®Google Scholar
• Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55:791 - 9; http://dx.doi.org/10.1016/S0895-4356(02)00448-1; PMID: 12384194
   PubMed Web of Science ®Google Scholar
• Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PGN, van de Water HPA, et al. Disability weights for disease in The Netherlands. Amsterdam Medical Centre, Institute for Social Heatlh Care, Amsterdam. 1997.
   Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172. The University of York Centre for Health Economics. 1999. Available at: http://www.york.ac.uk/inst/che/pdf/DP172.pdf.
   Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365 - 7; http://dx.doi.org/10.1016/S0140-6736(04)16725-1; PMID: 15276396
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30:566 - 9; http://dx.doi.org/10.1097/INF.0b013e31820e8638; PMID: 21326136
   PubMed Web of Science ®Google Scholar
• de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One 2010; 5:e12144; http://dx.doi.org/10.1371/journal.pone.0012144; PMID: 20730091
   PubMed Web of Science ®Google Scholar
• Van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM, de Melker HE. Immunization coverage National Immunization Programme in the Netherlands [in Dutch]. Bilthoven, the Netherlands: National Institute of Public Health & the Environment (RIVM); 2012.
   Google Scholar
• Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27:Suppl 2 B3 - 12; http://dx.doi.org/10.1016/j.vaccine.2009.04.071; PMID: 19481313
   PubMed Web of Science ®Google Scholar
• Jackson C, Lennon D, Wong S, Yan J, Stewart J, Reid S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011; 96:744 - 51; http://dx.doi.org/10.1136/adc.2009.180596; PMID: 21596727
   PubMed Web of Science ®Google Scholar
• Neppelenbroek SE, de Vries M, de Greeff SC, Timen A. 'da's goed gedaan?' Woordverslag van de landelijke vaccinatiecampagne meningokokken C, 2002 [in Dutch]. GGD Nederland; ISBN 90-72279-38-X. 2003.
   Google Scholar
• Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther 2010; 32:1517 - 32; http://dx.doi.org/10.1016/j.clinthera.2010.06.016; PMID: 20728764
   PubMed Web of Science ®Google Scholar